Racial, Ethnic Differences ID'd for Idecabtagene Vicleucel in Multiple Myeloma
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 25, 2023 -- There are some racial and ethnic differences in safety and response to standard of care (SOC) idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM), according to a study published online Oct. 16 in Blood Advances.
Lauren C. Peres, Ph.D., from the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and colleagues pooled data from 207 RRMM patients (28 percent racial and ethnic minority patients [11 percent Hispanic; 17 percent non-Hispanic Black]) treated with SOC ide-cel across 11 institutions to examine clinical outcomes.
The researchers found that non-Hispanic Black patients had higher median levels of C-reactive protein and baseline ferritin than Hispanic and non-Hispanic White patients, and they were more likely to develop cytokine release syndrome. The best overall response rate was lower among Hispanic versus non-Hispanic Black and White patients (59 percent versus 86 and 86 percent, respectively), but no differences were seen in progression-free or overall survival.
"These results highlight the need for diverse patient cohorts in research and clinical trials," Peres said in a statement. "Clinical trials often lack diversity for many reasons such as recruitment barriers, financial considerations, medical mistrust, and cultural insensitivity. But stringent trial eligibility criteria also often exclude racial and ethnic minorities. In fact, 75 percent of our study population would not have been eligible for the trial that led to the U.S. Food and Drug Administration approval of ide-cel."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Persistent Sociodemographic Differences Seen in Use of AutoHCT for Multiple Myeloma
WEDNESDAY, May 8, 2024 -- Sociodemographic differences persist in utilization of autologous hematopoietic cell transplantation (autoHCT) for multiple myeloma, according to a study...
FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma
TUESDAY, April 9, 2024 -- The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed...
Survival 21 Percent a Year After ICU Discharge for Blood Cancer Patients
THURSDAY, March 21, 2024 -- For hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.